Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
Provided By GlobeNewswire
Last update: Nov 4, 2025
-- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million --
-- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity --
Read more at globenewswire.com99.47
-5.52 (-5.26%)
Find more stocks in the Stock Screener
RYTM Latest News and Analysis
2 days ago - By: Chartmill
